Somatropin - Genentech

Drug Profile

Somatropin - Genentech

Alternative Names: Nutrophin; Nutropin; Nutropin Aq; NutropinAq; SMP 140

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Dainippon Sumitomo Pharma; Genentech; Ipsen; Roche
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Short stature; Somatotropin deficiency; Turner's syndrome
  • No development reported Fibromyalgia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Somatotropin-deficiency in European Union (SC, Controlled release)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 16 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top